Toxicological Potential of the FDA-Approved Treatment against Monkeypox. Comment on Zovi et al. Pharmacological Agents with Antiviral Activity against Monkeypox Infection. <i>Int. J. Mol. Sci</i>. 2022, <i>23</i>, 15941

Toxicological Potential of the FDA-Approved Treatment against Monkeypox. Comment on Zovi et al. Pharmacological Agents with Antiviral Activity against Monkeypox Infection. <i>Int. J. Mol. Sci</i>. 2022, <i>23</i>, 15941

Recently, some drugs were approved to control Monkeypox (MPX), among them tecovirimat. This was recently approved by regulatory agencies around the world, the paper of Zovi et al entitled <i>Pharmacological Agents with Antiviral Activity against Monkeypox Infection</i> highlight it as sa...

Full description

Bibliographic Details
Main Authors: Gabriel Christian de Farias Morais, Umberto Laino Fulco, Edilson Dantas da Silva, Claudio Bruno Silva de Oliveira, Jonas Ivan Nobre Oliveira
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:International Journal of Translational Medicine
Subjects:
Monkeypox
tecovirimat
physicochemical descriptors
pharmacokinetic
toxicity
ADME-T
Online Access:https://www.mdpi.com/2673-8937/3/2/13

Internet

https://www.mdpi.com/2673-8937/3/2/13

Similar Items